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Abstract
Pituitary function has been shown to be regulated by an increasing number of intra-pituitary factors
including cytokines. Here we show that the important cytokine TNF-α activates prolactin gene
transcription in pituitary GH3 cells stably expressing luciferase under control of 5 kb of the human
prolactin promoter. Similar regulation of the endogenous rat prolactin gene by TNF-α in GH3 cells
was confirmed using real time PCR. Luminescence microscopy revealed heterogeneous dynamic
response patterns of promoter activity in individual cells. In GH3 cells treated with TNF-α, western
blot analysis showed rapid IκBα degradation and phosphorylation of p65. Confocal microscopy of
cells expressing fluorescence labelled p65 and IκBα fusion proteins showed transient cytoplasmic-
nuclear translocation and subsequent oscillations in p65 localisation and confirmed IκBα
degradation. This was associated with increased NF-κB mediated transcription from an NF-κB
responsive luciferase reporter construct. Disruption of NF-κB signaling by expression of dominant
negative variants of IKKs or truncated IκBα abolished TNF-α activation of the prolactin promoter,
suggesting that this effect was mediated by NF-κB. TNF-α signaling was found to interact with other
endocrine signals to regulate prolactin gene expression, and is likely to be a major paracrine
modulator of lactotroph function.
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Introduction
The human prolactin gene is located on the short arm of chromosome 6 (1) and consists of five
coding exons within a region of 10 kb. It is expressed in lactotroph cells in the anterior pituitary,
but is also expressed in the endometrium (2;3) and myometrium (4) of the uterus and in
lymphoid cells (5;6). In pituitary cells, prolactin gene expression is regulated in response to
multiple hormonal signals by an extensive 5’-flanking region extending 5000 bp upstream from
the transcriptional start site, containing multiple binding sites for Pit-1 (7-10). Prolactin mRNA
transcribed in extra-pituitary tissues contains an additional non-coding exon 1a, and expression
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is regulated by an alternate upstream promoter. Pituitary prolactin expression in vivo is
regulated by dopamine and other hypothalamic factors such as TRH and by an increasing
number of intrapituitary factors (11). In addition to growth factors, such as FGF-2 or EGF and
other proteins like galanin, recent evidence has shown that cytokines are also expressed in the
pituitary gland and are likely to act as important paracrine or autocrine regulators of pituitary
function (11;12).
Tumor necrosis factor-α (TNF-α) is a cytokine that plays a role in a variety of biological
processes including cell proliferation, differentiation and apoptosis. Furthermore it can activate
transcription factors such as NF-κB and AP-1 (13). NF-κB transcription factors consist of
homo- or heterodimers assembled from subunits including p50, p52, p65, c-Rel and Rel B
(14) and are involved in the regulation of many genes (15). In the cytoplasm NF-κB is bound
by inhibitory proteins (IκB proteins) that block its nuclear localization domain (14). Activation
of IκB kinases IKKα and IKKβ (16) leads to phosphorylation of IκBs which targets them for
rapid degradation by the proteasome (17). The released NF-κB dimers can then translocate to
the nucleus and regulate target gene transcription.
TNF-α is expressed in multiple tissues including brain and pituitary (18). In the pituitary,
expression of TNF-α has been found in the intermediate lobe and in somatotroph cells (19).
The presence of TNF-α receptors in the pituitary cells has also been reported in vitro and in
vivo (20;21), suggesting that TNF-α might well play a role as an autocrine or paracrine
regulator.
Studies on the effect of TNF-α on the secretion of pituitary hormones have revealed an effect
on ACTH, GH, TSH and prolactin release (12;22). The results regarding the effect on prolactin
are conflicting. Using mouse hemipituitaries, Milenkovic et al. showed no effect (23), whereas
others using dispersed primary rat pituitary cells showed an decrease (24;25) or an increase
(26;27) in prolactin release after TNF-α treatment.
Here we report that TNF-α is a potent activator of prolactin promoter activity in pituitary cells,
with a biphasic effect over 6-24h. Heterogeneous patterns of response in individual cells led
to the observed averaged population response. The effect of TNF-α is associated with activation
of NF-κB and could be blocked by co-expressing dominant negative isoforms of components
of the NF-κB signaling pathway. The effects of TNF-α were amplified by simultaneous
treatment with a range of other hormonal stimuli, suggesting a physiological role as a major
modulator of other signaling pathways in determining physiological outcome.
Material and Methods
Plasmids
Plasmids expressing the transdominant negative IKKα, IKKβ and NEMO/IKKγ were a gift
from Dr. N. Inohara (University of Michigan, USA; (28). The expression plasmid for truncated
IκBα (missing the 40 NH2-terminal amino acids) was a kind gift from Dr. E. Costello
(University of Liverpool), and the wild type IKKβ was from Dr. C. Paya (Mayo Clinic,
Rochester, USA (29). The pNF-κB-luc plasmid was from Stratagene (La Jolla, USA). The
fluorescent CMV-IκBα-EGFP, NF-IκBα-EGFP and CMV-p65-dsRedXP fusions protein
vectors were described previously (30;31).
Cell culture and luciferase assays
The construction of the GH3/hPrl-luc cell line was described previously (32). Cells were
maintained in DMEM with pyruvate/glutamax (Life Technologies Inc., Paisley, UK) and the
addition of 10% FCS (Harlan Sera-Lab, Crawley Down, UK). Except for TNF-α and FGF-2
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(Merck Biosciences Ltd., Nottingham, UK) all other reagents were obtained from Sigma
(Sigma Aldrich Corp. Ltd., Dorset, UK).
For transient transfections 1.2 × 106 GH3 cells were grown in 10-cm dishes for 24h and then
transfected using Fugene 6 (Boehringer Mannheim/Roche, Germany) according to the
manufacturer’s protocol. For cotransfection studies the total amount of DNA used was held
constant by addition of empty expression vector. After 24h cells were trypsinized and seeded
onto 24-well plates.
For luciferase assays 105 cells/well were grown in 24-well plates, serum starved for 24h and
then stimulated as indicated. Cells were washed twice with ice cold PBS and lysates (Tris/
PO4 25 mM, MgCl2 10 mM, EDTA 5 mM, 15% glycerol, 0.1% Triton X100, 0.1 mg/ml BSA)
were prepared. The luciferase activity was measured using a Berthold Mithras 960 luminometer
(Berthold Technologies, Redbourn, UK). 4-8 replicates were analysed for each treatment group
and experiments were performed at least 3 times. Results are shown as mean fold induction ±
standard deviation of at least three independent experiments. For statistical analysis P-values
were calculated using Student’s t-test.
Real-time PCR
For real-time PCR analysis GH3 cells were grown in 25cm2 flasks (∼ 5 × 106 cells), serum
starved for 24h and then stimulated with 10 ng/ml TNF-α for the indicated times. Cells were
harvested by trypsinization and washed twice in ice cold PBS. Total RNA was isolated using
the QIAGEN RNAeasy Kit (QIAGEN, Hilden, Germany) and cDNA was generated with the
Omniscript RT system (QIAGEN). Quantitative real time PCR using the Stratagene Mx3000
P thermocycler (Stratagene) and the SYBRgreen Jump Start Taq Ready Mix (Sigma) was
performed as follows: 10 min at 95 °C followed by 40 cycles of 15 s at 95 °C, 1 min at 56 °C
and 30 s at 72°C. The following primers were used for cyclophilin,
TTTTCGCCGCTTGCTGCAGAC and CACCCTGGCACATGAATCC-TGGA, and
prolactin, AGCCAAGTGTCAGCCCGGAAAG and TGGCCTTGGCAATAAACTCACGA
and resulted in amplicons of 217 bp and 227 bp, respectively. The dissociation curves of used
primer pairs showed a single peak and samples after PCR reactions had a single DNA band of
the expected size in an agarose gel. Cyclophilin was used as a housekeeping gene for
normalization. Data are shown as average of three independent experiments ± standard
deviation.
Real time luminescence imaging
GH3/hPrl-luc cells (105) were seeded onto 35-mm glass coverslip-based dishes(IWAKI,
Tokyo, Japan) and cultured in 10% FCS and then serum starved for 24h before imaging.
Luciferin (final concentration,1 mM; Bio-Synth, Inc., Staad, Switzerland) was added at least
10h prior to the start of the experiment, and the cells were transferred to the stage of a Zeiss
Axiovert 100M (Carl Zeiss, Welwyn Garden City, UK) in a dark room. The cells on the stage
were maintained at 37°C in a Zeiss incubator M with 5% CO2-95% air. Bright field images
were taken before and after luminescence imaging to allow localisation of the cells.
Luminescence images were obtained using a Fluar x20, 0.75 numerical aperture, dry objective
and captured using a photon counting charge coupled device camera (Orca II, Hamamatsu
Photonics, Welwyn Garden City, UK). Sequential images, integrated over 30 min, were taken
using 4 by 4 binning and acquired using Kinetic Imaging software AQM6 (Andor, Belfast,
UK). 10 ng/ml TNF-α was added directly to the dish immediately before commencing the
experiment.
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Analysis was carried out using Kinetic Imaging software AQM6. Regions of interest were
drawn around each single cell and total photon counts for individual cell areas were integrated
over 30 min intervals. Mean intensity data was collected after the average instrument dark
count (corrected for the number of pixels being used) was subtracted from the luminescence
signal.
Data were analyzed using the Cluster peak detection algorithm (33) to detect significant peaks
[>12 (background + 2 SD)]in luciferase activity. Further data analysis was performed with
Excel and SPSS statistics package (SPSS, Inc., Chicago, IL, USA).
Western blotting
GH3 cells were seeded in 60mm dishes at a density of 2×106 cells in 6ml and serum starved
for 24h before stimulation. Separate dishes were stimulated with 10 ng/ml TNF-α for the
indicated times. Cells were washed with ice cold PBS and lysed with ice cold lysis buffer (1%
sodium dodecyl sulphate [SDS]; 10% glycerol; 1% β-mercaptoethanol; 62.5 mM Tris-HCl,
pH 6.8) containing a protease and phosphatase inhibitor cocktail (Sigma, Poole, UK). Samples
were collected, heated at 100°C for 5 mins and sonicated for 10 sec. Proteins were separated
by electrophoresis on SDS-polyacrylamide (7.5%) gels and electro-transferred onto
nitrocellulose. Non-specific binding sites were blocked with 5% dried skimmed milk in 0.05%
Tween-20 supplemented Tris-buffered saline (TTBS; 25 mM Tris HCl, pH 8.0, 150 mM NaCl).
Nitrocellulose membranes were incubated overnight at 4°C with either phospho-p65, p65 or
IκBα monoclonal antibodies (Cell Signaling, Beverly, MA, USA). The membranes were then
washed extensively in TTBS and incubated with goat anti-rabbit immunoglobulin G conjugated
to horseradish peroxidase for 1h at room temperature, following by extensive washing in TTBS.
Positive immunoreactive bands were detected by chemiluminescence using SuperSignal®
West Pico according to the manufacturer’s instructions (Pierce Biotechnology, Rockford, IL,
USA).
Detection of transcription factor activation
GH3 cells were seeded in 60mm dishes at a density of 2×106 cells in 6ml and serum starved
for 24h before stimulation. Separate dishes were stimulated with 10 ng/ml TNF-α for the
indicated times. A TransAM NF-κB p65 Chemi transcription factor assay kit (Activemotif,
Belgium) was used according to the manufacturer’s instructions. Briefly, the kit comprised a
96-well plate with immobilised NF-κB consensus binding site oligonucleotide. Cells were
lysed with 100 μl of the provided lysis buffer and 10μl of lysed sample was used per well.
Activated NF-κB from the whole cell extracts specifically bound to the oligonucleotide and
was detected using an antibody against the p65 subunit. A secondary antibody conjugated to
horseradish peroxidase provided a chemiluminescent readout. Jurkat nuclear extract was used
as a positive control (data not shown), and a blank well was run for background luminescence
subtraction. All reactions were performed in duplicate, and results are shown as the average
of 2 independent experiments ± SEM.
Real time fluorescence imaging
GH3 cells (2×105) were seeded onto 35-mm glass based dishes(IWAKI) and cultured in 10%
FCS. After 24h cells were transiently transfected with CMV-p65-dsRedXP and either CMV-
IκBα-EGFP or NF-IκBα-EGFP (driven by 5 tandem repeats of a consensus NF-κB binding
site (30) using Fugene 6. Cells were imaged 24h after transfection on a Zeiss Axiovert 200
equipped with an XL incubator (maintained at 37C, 5% CO2, in humid conditions) through a
63x objective (NA = 1.4, Zeiss). Excitation of EGFP was performed using an Argon ion laser
at 488nm. Emitted light was captured through a 505-550 nm bandpass filter from a 545 nm
dichroic mirror. DsRed-XP fluorescence was excited using a Helium Neon laser (543 nm) and
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detected through a 560 nm longpass filter. Images were taken every 5min. Data was captured
and analysed using LSM510 software.
Results
TNF-α activates the human prolactin promoter
To evaluate the role of TNF-α in the transcriptional regulation of pituitary prolactin expression
we have used GH3 cells stably expressing luciferase under the control of a 5000 bp fragment
of the human prolactin promoter (32). This promoter is activated by TNF-α in a dose dependent
manner, with maximal effects seen at 2ng/ml (P < 0.05), with significantly greater induction
at 24h compared to 6h (Fig 1A). GH3 cell lines expressing luciferase under the control of a
500 bp GH promoter fragment showed no response to TNF-α, confirming the specificity of
this response, and that it was not an artefact due to cryptic response elements in the reporter
vector (Fig 1A, inset panel). Detailed time course experiments showed a clear biphasic response
of transcription, with a transient plateau between 6-12h (P < 0.05 after 2h) and a second plateau
reached by 24h (Fig. 1B). To test whether the endogenous rat prolactin gene is also activated
by TNF-α, GH3 cells were treated with TNF-α, total RNA prepared and subjected to real time
PCR analysis. These experiments revealed that the endogenous rat prolactin gene is activated
by TNF-α in a similar manner to the human prolactin promoter reporter gene construct, with
a similar magnitude and time-course of response (Fig. 1C).
Dynamics of transcriptional response in single cells
Previous work has shown that gene promoter activity in individual living cells is highly
unstable and frequently pulsatile (32;34;35). Therefore, in order to analyse the contribution of
single cells to the overall population response that was seen using analysis by luminometry,
GH3/prl-luc cells were imaged for 48h either in resting conditions or after stimulation with
TNF-α, and Cluster analysis of the transcriptional response in single cells was performed (n =
116 cells from 7 experiments for TNF-α treatment, and n= 75 cells from 4 experiments for
resting conditions). Microscopic analysis of whole fields of cells confirmed the biphasic
response pattern observed using luminometry (Fig. 2A). Single cell analysis revealed a
heterogeneous response of individual cells to the TNF-α treatment that could be classified into
three predominant patterns, an early peak, a late peak or more than one peak in promoter
activity. Examples of individual cells showing the three typical patterns observed are shown
in Fig. 2C-E. Cluster analysis of the single cell data showed a significant peak in transcription
after TNF-α treatment between 0-14h (termed period 1) for 41 ± 4% of the cells (compared to
20 ± 8% under resting conditions); 20-34h after addition of TNF-α (termed period 2), 59 ± 7%
of cells showed a pulse in transcription (compared to 20 ± 4% control). 16 ± 5% of TNF-α
treated cells (compared to 55 ± 8% control) showed no peak during the whole experiment (Fig.
2B). Significant peaks in both time periods were observed in 30 ± 3% (compared to 4 ± 1%)
of the cells. These data suggest that the increase in transcription after TNF-α treatment is due
to activation of more cells rather than due to a simultaneous graded increase of expression
levels in all cells.
TNF-α activates the NF-κB signaling pathway in GH3 cells
To test whether the activation of the prolactin promoter could be mediated by NF-κB we first
wanted to establish whether TNF-α can activate NF-κB in pituitary GH3 cells. Western blot
analysis for p65, phospho-p65 and IκBα was performed with lysates from GH3 cells treated
with TNF-α for 0-2h (Fig. 3A). There was no change in the level of total p65, but treatment
with TNF-α led to a rapid transient increase in phosphorylation of p65 that lasted for
approximately 30 min and was followed by a decrease below basal levels. Degradation of
IκBα was observed after 20-30 min with subsequent recovery to pre-treatment level after 2h.
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Using a DNA/protein interaction assay for p65 we found an increase in complex formation
using lysates from GH3 cells treated with TNF-α for 30-60 min (Fig. 3B). To show that
IκBα degradation and p65 phosphorylation after TNF-α stimulation was associated with
transcriptional activation, GH3 cells were transiently transfected with a reporter construct
containing 5 repeats of the NF-κB consensus binding sequence linked to the luciferase gene
(pNF-κB-luc). Treatment of these cells with TNF-α caused a time- (Fig. 3C) and dose-
dependent (data not shown) increase in luciferase activity (P < 0.05 at 2h and later). These data
indicate that TNF-α is indeed able to stimulate gene transcription via activation of the NF-κB
signaling pathway in GH3 cells. We then transiently transfected GH3 cells with expression
vectors encoding p65-DsRedXP and IκBα-EGFP under the control of the strong human
Cytomegalovirus promoter (CMV) (30;31) and used dual fluorescence time-lapse imaging to
observe and quantitate dynamic changes in the nuclear : cytoplasmic localisation ratio (N:C)
of p65 and the level of cytoplasmic IκBα in single transfected cells. TNF-α treatment led to
rapid degradation of IκBα and nuclear translocation of p65 (Fig. 3D). Subsequent oscillations
in the level of nuclear p65 were seen in ∼60% of cells (11 out of 18 cells) with a period of
around 90 minutes (Fig. 3E), similar to those reported in other cell lines (31). We repeated
these experiments using NF-IκBα-EGFP (driven by 5 tandem repeats of a consensus NF-κB
binding motif; as previously described (31) alongside CMV-p65-DsRedXP. Addition of TNF-
α to the medium led to a rapid decrease in cytoplasmic IκBα reaching a minimum after 1h, and
subsequent recovery to pre-treatment levels after approximately 2h. The degradation of IκBα
was accompanied by a transient nuclear translocation of p65 as before (Fig. 3F-G).
TNF-α activation of the prolactin promoter is mediated by the NF-κB signaling pathway
To test whether the observed activation of the human prolactin promoter is mediated via this
pathway, we co-transfected the 5000 bp human prolactin promoter reporter construct into GH3
cells together with a well characterised set of expression vectors encoding wild type and
dominant negative components of the NF-κB signaling pathway (Fig. 4) that have previously
been used to investigate the role of NF-κB in Cyclin D1 transcription (36). Cotransfection of
wild type IKKβ led to an increase in basal expression levels from the prolactin promoter but
no change in fold induction (Fig. 4A). On the other hand, dominant negative IKKβ abolished
the induction by TNF-α completely and slightly decreased basal expression (Fig. 4B).
Expression of dominant negative NEMO/IKKγ (16) or truncated IκBα (Δ IκBα) also abolished
the increase in transcription after TNF-α treatment but had no effect on basal expression levels
(Fig. 4C-D). Dominant negative IKKα also had no effect on basal levels and had a reduced
inhibitory effect on the response to TNF-α (Fig. 4E). Co-transfection of these constructs did
not alter activation of the prolactin promoter by FGF-2 or forskolin (Fig. 4F). Taken together,
these data suggest that the TNF-α stimulation of the prolactin promoter is mediated via the NF-
κB pathway.
TNF-α interacts with other signaling pathways to modulate prolactin gene expression
As TNF-α is a potent stimulus of the human prolactin promoter we analysed its interactions
with other physiologically important positive or negative regulators of prolactin gene
expression such as FGF-2 and glucocorticoids (9;37). GH3/prl-luc cells were treated with
FGF-2, dexamethasone or estradiol, alone or in combination with TNF-α (Fig. 5). Treatment
of GH3/hPrl-luc cells with 10 ng/ml FGF-2 alone led to an approximately 2 and 8 fold increase
in luciferase activity after 6h and 24h respectively. TNF-α and FGF-2 in combination led to a
further increase in promoter activation (Fig. 5A), suggesting that FGF-2 and TNF-α act
independently and utilize different signaling pathways. This is further supported by the fact
that whereas TNF-α was able to induce expression of luciferase from the pNF-κB-luc reporter
construct, FGF-2 was not (data not shown), indicating that FGF-2 unlike TNF-α does not
activate NF-κB.
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Glucocorticoids are known to decrease prolactin expression (9;38) and have been shown to
interact with NF-κB signaling in a variety of systems (39;40). In GH3/hPrl-luc cells treatment
with 10 nM dexamethasone had no effect on luciferase activity after 6h but decreased gene
expression by about 50% after 24h. When given in combination with TNF-α, dexamethasone
completely abolished the TNF-α induction of the human prolactin promoter not only after 24h
but also after 6h (Fig. 5B). In contrast, in GH3 cells transiently transfected with the pNF-κB-
luc reporter construct dexamethasone failed completely to repress TNF-α activation (inset Fig.
5B). This is in marked contrast to the inhibitory effect of GR stimulation on TNF-α induction
of this promoter in other cells such as HeLa cells (39).
Whereas previous studies have revealed an estrogen response element in the rat prolactin
promoter, studies on the human prolactin promoter so far have not shown major effects of
estrogen (9;41). Treatment of GH3/hPrl-luc cells with 10 nM estradiol alone or in combination
with 10 ng/ml TNF-α had no effect on the activity of the human prolactin promoter after 6h.
After 24h, estradiol gave a consistent but small 1.5-fold induction, however in combination
with 10 ng/ml TNF-α, estradiol led to a synergistic 2-3 fold increase in gene activation (Fig.
5C).
Discussion
Here we have reported that TNF-α activates the human prolactin gene promoter in GH3
pituitary cells, and significantly modulates the effects of other important physiological
regulators of prolactin expression such as estrogen, FGF-2 and glucocorticoids. Cotransfection
studies with dominant negative proteins of the NF-κB signaling pathway have shown that this
regulation is mediated via NF-κB.
Prolactin gene expression is regulated by various hypothalamic factors, but in recent studies
an increasing number of intrapituitary factors have also been identified as important regulators
(11). Here we show for the first time that in pituitary GH3 cells the cytokine TNF-α is able to
activate the prolactin promoter in a dose- and time-dependent manner, and also that expression
of the endogenous rat prolactin gene is similarly stimulated by TNF-α. As prolactin is thought
to play a role in the stress response, our data, together with findings showing expression of
TNF-α (18;19) and its receptors (20;21) in the pituitary, suggest that TNF-α might be an
important paracrine or autocrine factor involved in the modulation of prolactin expression.
Studies of TNF-α effects on prolactin using primary pituitary cells have so far focused on
hormone secretion and shown conflicting results (23-27). The discrepancy in these studies is
most likely due to differences in the experimental design and model systems used. A recent
study on primary lactotrophs from female rats showed an apoptotic effect of TNF-α (42), but
used much higher (50 ng/ml) concentrations than we have employed (2-10ng/ml). Using flow
cytometry we have seen no evidence of increased apoptosis in GH3 cells with 10ng/ml TNF-
α for periods up to 30h (data not shown). However, the effect of TNF-α on prolactin gene
expression in primary cell cultures or in vivo remains the subject of further investigation.
We and others have found that gene promoter activity in clonal pituitary cell lines is highly
dynamic and variable among different individual cells, with rapid fluctuations in transcriptional
activity in resting cells as well as in hormone treated cells (32;43). This is a phenomenon also
found in normal pituitary cells using microinjection of reporter plasmids (44) or transfection
with recombinant adenoviruses (34). Here we show that stimulation of GH3/hPrl-luc cells with
TNF-α is accompanied by heterogeneous changes in prolactin promoter activity, with increased
proportions of cells displaying transient peaks or pulses in transcription, with the overall effect
that more cells become transcriptionally active. The cells in our study were a clonal cell line,
as opposed to a mixed population of cells seen in the normal pituitary gland: thus the
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heterogeneity we have seen arises from different transcriptional patterns amongst individual
cells in a single cell population. All of the cells in the population can express the transgene,
but at varying levels, so that some cells exhibiting very low levels of gene expression at a given
time may then become transcriptionally active at different rates and time points after a stimulus.
There are two theoretical mechanisms to regulate transcription from a gene promoter.
Transcriptional enhancers might increase the probability that a promoter is active, meaning
that genes are either ‘off’ or ‘on’ (binary behaviour), or they might increase the rate of gene
transcription modulating a continuous range of activity (45;46). Studies in yeast suggest that
a promoter can adopt either binary or graded behaviour depending on the signalling pathway
involved (47). The data we report here would favour a stochastic (or binary) model of gene
transcription, as we have found an increased number of transcriptionally active cells after the
stimulation with TNF-α rather than a simultaneous graded increase in promoter activity in all
cells. Furthermore, the cells showed transient peaks of activity with a substantial number of
cells showing more than one peak rather than constant transcription levels, underlining the
stochastic nature of this process. These stochastic changes in transcription phenotype in single
cells are most likely caused by the relative instability of transcription complexes. This would
be consistent with recent findings of dynamic recruitment and release of transcription
regulators to chromatin (48;49). Stochastic patterns of transcription may be physiologically
important in determining the way in which cells integrate their patterns of response to
combinations of physiological regulators (50).
TNF-α can activate transcription factors such as AP-1 and NF-κB, which may override the
apoptotic pathways (13). Stimulation of NF-κB activates the IKK signalsome which
phosphorylates IκB and NF-κB proteins, leading to ubiquitination and degradation of IκB and
subsequent translocation of free NF-κB dimers to the nucleus (14;17). In agreement with this
we found rapid phosphorylation and transient nuclear translocation of p65 as well as
degradation of cytoplasmic IκBα in TNF-α stimulated GH3 cells. In agreement with our
previous studies in other cell types (30) we observed highly damped oscillations in the level
of nuclear NF-κB which had a period of around 90 minutes. These cycles of NF-κB
translocation have been associated with cycles of re-activation of NF-κB (measured by Ser536
phosphorylation) that maintain NF-κB-dependent gene expression. As described in other cell
types (30) the use of a consensus NF-κB promoter in front of the IκBα-EGFP reporter led to
oscillations in cytoplasmic EGFP fluorescence level and an increase in p65 oscillation period
(data not shown). Indeed, using NF-κB responsive reporter gene constructs we showed that
NF-κB translocation and IκBα-degradation is accompanied by dose- and time-dependent
increase in NF-κB-mediated transcription. These findings are supported by a previous study
showing increased protein/DNA complex formation in electrophoretic mobility shift assays
using nuclear extracts from GH3 cells treated with TNF-α (51). Taken together, our evidence
strongly suggests that TNF-α is able to activate the NF-κB signaling pathway in GH3 cells.
Activity of the IKK complex is crucial for the activation of NF-κB (16). Disruption of its
activity by expression of dominant negative variants of IKKα or IKKβ has been used in
previous studies to show NF-κB involvement in transcriptional regulation of the Cyclin D1
gene (36). Here we found that expression of dominant negative IKKs abolished induction of
the prolactin promoter activity by TNF-α in GH3 cells, suggesting that the TNF-α effect
specifically is mediated by NF-κB. This is further supported by our finding that expression of
a truncated form of IκBα (ΔIκBα) that cannot be phosphorylated/degraded (and therefore
abolishes NF-κB activation by preventing its translocation to the nucleus) also blocks activation
of the prolactin promoter by TNF-α. Forskolin and FGF-2 regulation of the prolactin promoter
were independent of NF-κB. This was expected from previous reports showing that regulation
by FGF-2 involves a Rac1, PLCγ, PKCδ and ERK dependent mechanism (52), while forskolin
increases intracellular cAMP levels to activate PKA.
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Our results show that TNF-α not only activates the human prolactin promoter, but also interacts
with other well-known regulators of prolactin expression. Simultaneous treatment of GH3/
hPrl-luc cells with TNF-α and FGF-2 led to a significant additive effect on promoter activation.
FGF-2 did not activate NF-κB in pituitary GH3 cells, and therefore independent activation of
distinct signaling pathways may explain the additional effect. Dexamethasone blocked
activation of the prolactin promoter by TNF-α. The repressive effect of glucocorticoids on the
expression of prolactin involves interaction between Pit-1 and GR but binding of GR to DNA
is not required (38). The loss of activation by TNF-α in the presence of dexamethasone could
therefore be explained by either loss of NF-κB transactivation due to negative cross-talk with
GR, or by independent glucocorticoid repression of the prolactin promoter overriding the TNF-
α activation. In contrast to results in other cell types (39) dexamethasone did not alter
transcriptional activation of a reporter gene construct containing 5 NF-κB response elements
by TNF-α in GH3 cells, arguing against a direct effect of GR on NF-κB signaling pathways in
these cells, and suggesting that this effect was characteristic of the prolactin promoter but not
of a consensus NF-κB promoter. Bioinformatic analysis has revealed two potential NF-κB
binding sites at -1300/-1309 and -3810/-3819bp in the human prolactin promoter, but
preliminary experiments suggest that they may not be involved in these effects of TNF-α (data
not shown), suggesting that a more complex mechanism may be involved, as shown for other
genes such as IL-6 and COX-2 (53-55). NF-κB regulation of prolactin might therefore involve
other factors, and the discrepancy in dexamethasone repression seen here may be explained by
GR blocking interaction of NF-κB with some yet unknown factor. Understanding of this
interesting behaviour requires further more detailed study.
Despite the effect of estrogen on the rat prolactin promoter (41) and the well known in vivo
effect on prolactin production in man, previous studies have shown little or no estrogen effect
on human prolactin promoter activity (9;41). Here we show a small but consistent activation
of the prolactin promoter by estrogen after 24h, but not after 6h. Interestingly, compared to
treatment with either TNF-α or estrogen alone, stimulation of GH3/hPrl-luc cells with a
combination of both stimuli led to a synergistic large increase in promoter activity. Recent
studies have demonstrated molecular cross talk between estrogen receptor (ER) and NF-κB
(52). Most studies have found inhibition of NF-κB signaling by ER and suggested a series of
molecular mechanisms for this antagonism including direct inhibition of DNA binding, effects
of the ER on IκB processing, or interference with coactivator recruitment (56). Synergistic
interaction between estrogen and NF-κB signaling appears to be unusual, but has previously
been shown for the serotonin 5HT1A receptor promoter (57). It will be interesting to determine
the molecular mechanisms by which ER and NF-κB may differentially cross-regulate their
effects in different cell types and at different promoters. This interaction between TNF-α and
estrogen is likely to be biologically important, given the major role of estrogen in normal
pituitary physiology, and possibly in pituitary adenoma formation.
In conclusion, we have shown for the first time that TNF-α can activate the human prolactin
promoter and that this effect is mediated by NF-κB. TNF-α and TNF-α receptors are produced
locally in the pituitary gland (18-21) suggesting that this effect could be important in vivo. We
show that other important physiological regulators of prolactin expression, such as estrogen,
interact with TNF-α in order to give rise to synergistic regulation of prolactin expression. Taken
together, these data suggest that TNF-α and NF-κB regulation of the prolactin gene is likely
to be important for pituitary physiology in vivo.
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Fig 1.
Dose and time dependent activation of the prolactin promoter by TNF-α. GH3/hPrl-luc cells
were serum starved for 24h. Cells were then treated with the indicated doses of TNF-α for 6h
(◆) and 24h (□) (A) or with 10 ng/ml TNF-α (◆) or not (□) for the indicated time periods (B).
(Inset A) GH3 cells expressing luciferase under the control of 5000 bp of the hPrl or 500 bp
of the hGH promoter were treated with TNF-α for 6h. Basal expression levels for the hPrl
promoter construct under these conditions were 5-10 times higher than for the hGH promoter.
Cells were lysed and luciferase activity measured by luminometry. (C) GH3 cells were treated
as above with TNF-α for the indicated times. Cells were harvested, RNA prepared and
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subjected to real time PCR analysis. Data were normalized using expression of the
housekeeping gene cyclophilin. Results shown are the means ± SD from at least three
independent experiments; * P < 0.05.
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Fig 2.
Real time luminescence imaging showed heterogeneous transcriptional responses in individual
cells after TNF-α treatment.
GH3/hPrl-luc cells were cultured in 35 mm glass coverslip culture dishes, serum starved for
24h and then imaged for 48h following stimulation with 10 ng/ml TNF-α (◆) or not (□). (A)
The mean of the total photon counts obtained from a whole microscopic field of cells (about
20 per field): shaded areas indicate the two time periods used to categorise cells into different
patterns of expression. (B) Single cell transcriptional responses with or without TNF-α
stimulation were classified into four groups using Cluster analysis software. The groups were
defined as cells showing no significant response, all cells showing significant responses in
period 1, all cells showing significant responses in period 2, and cells showing significant
responses in both periods. Data shown are means ± SD from four or seven independent
experiments. (C-E) Examples of single cells representing the predominant response patterns
observed.
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Fig 3.
Analysis of NFκB activation by TNF-α in GH3 cells.
GH3 cells were serum starved for 24h before stimulation with 10 ng/ml TNF-α for the indicated
times. (A) Endogenous p65, phospho-p65 and IκBα levels were assessed by Western blotting
cell extracts using anti-p65, anti-phosho-p65 and anti-IκBα antibodies. (B) DNA/protein
interaction for p65 was analysed in lysates from TNF-α stimulated GH3 cells using a TransAM
NFkB p65 Chemi transcription factor assay kit. Results are shown as mean ± SEM of four
replicates from two independent experiments. (C) GH3 cells were transfected with the
pNFκB-luc reporter plasmid, serum starved for 24h and treated with 10 ng/ml TNF-α for the
indicated times. Results are shown as means ± SD from at least three independent experiments.
(D) Time course showing co-expression of p65-DsRedXP and CMV-IκBα-EGFP, in cells
stimulated with TNF-α at time zero. The movement of p65 is presented as the ratio of nuclear
to cytoplasmic fluorescent signal. The IκBα signal was normalised to resting levels at time
zero. (E) Examples of single cells showing oscillatory movement of p65 after TNF-α
stimulation. (F-G) GH3 cells were transfected with p65-dsRedXP and NF-IκB-EGFP,
stimulated with TNF-α and confocal images were taken every 5 min from living cells:
quantitative results (F) and images of typical cells (G) are shown at 0-120 min after addition
of TNF-α.
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Fig 4.
Cotransfection of dominant negative components of the NFκB signaling pathway with a human
prolactin promoter-luciferase construct.
Using GH3 cells the 5000 bp prolactin promoter-luc construct (1μg) was cotransfected with
the indicated amounts (0.1, 0.5, 1 μg) of expression plasmid for wildtype IKKβ, dnIKKβ,
dnIKKα, dnNEMO/IKKγ and a truncated IκBα(Δ IκBα). The total amount of DNA for each
transfection was kept constant by addition of empty expression vector (A-E). For (F), cells
were transfected with 1μg of 5000 bp prolactin promoter-luc construct and 1μg dnIKKβ,
ΔIκBα or dnNEMO. Cells were serum starved for 24h and then treated for 6h with 10 ng/ml
TNF-α (A-E) or the indicated stimuli (F); FGF 10 ng/ml, forskolin 1μM. Results are shown as
means ± SD of at least three independent experiments; * P < 0.05.
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Fig 5.
Combinatorial effect of TNF-α with FGF-2, dexamethasone or estradiol on prolactin promoter
activity.
GH3/hPrl-luc cells were serum starved for 24h and then stimulated for 6h or 24h with (A)
FGF-2 (10 ng/ml), (B) dexamethasone (10 nM), or (C) estradiol (0.1 nM) alone, in combination
with TNF-α (10 ng/ml), or TNF-α alone. Inset (B): GH3 cells were transfected with the
pNFκB-luc reporter construct, serum starved for 24h and treated with TNF-α and/or
dexamethasone for 6h. Results are shown as means ± SD of at least three independent
experiments; * P < 0.05.
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